Tenaya Therapeutics, Inc. 8-K

What Happened
Tenaya Therapeutics (TNYA) filed an 8-K (Item 1.02) reporting that on June 29, 2026 it entered into a Lease Termination Agreement with Terreno Park Union City LLC to end its lease for approximately 94,046 rentable sq. ft. at 33498 Central Avenue, Union City, CA (the Genetic Medicines Manufacturing Center, “GMMC Facility”). The lease, originally expiring July 2031, will now terminate on August 31, 2026. The company decommissioned the GMMC Facility in 2025 to reduce costs and cited available inventory of TN-201 and TN-401 to support ongoing clinical trials.

Key Details

• Lease termination agreement dated June 29, 2026; termination effective August 31, 2026.
• Company forfeited its $1,750,000 security deposit and will pay a one-time lease termination fee of approximately $294,200.
• GMMC Facility previously decommissioned in 2025; inventory of TN-201 and TN-401 expected to cover ongoing trials.
• Tenaya will retain internal process and assay development know‑how and plans to transfer AAV manufacturing to a contract development and manufacturing organization (CDMO) with global capabilities for future late‑stage development and/or commercial launch.

Why It Matters
This action removes a long‑term real estate obligation and reflects a shift from in‑house large-scale manufacturing to outsourced CDMO production, which the company says reduces costs. For investors, the near-term cash impact includes the forfeited deposit and termination fee (~$2.04M total); longer term, reliance on CDMOs may affect future manufacturing flexibility, costs, and timing for TN-201 and TN-401 development and potential commercialization.